Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis

Cited by papers we hold 9

• The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer · 2025
  No notice
• Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies · 2024
  No notice
• The crosstalk between copper-induced oxidative stress and cuproptosis: a novel potential anticancer paradigm · 2024
  No notice
• Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer · 2023
  No notice
• Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies · 2023
  No notice
• Cuproptosis: mechanisms and links with cancers · 2023
  No notice
• Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62–Keap1–NRF2 pathway · 2022
  Corrected
• Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective · 2022
  No notice
• System Xc−/GSH/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.